A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Conditional approval of sunitinib
Sunitinib malate (Sutent) is a small molecule ATP site-directed competitive inhibitor. It inhibits multiple processes necessary for tumour growth, including tumour cell proliferation and angiogenesis, through its action on multiple receptor tyrosinedoi:10.1016/j.ejcsup.2007.09.041 fatcat:k66xcqv42bcfzl37mwah44mcfa